Cleveland BioLabs
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch CBLI and buy or sell other stocks, ETFs, and their options commission-free!About CBLI
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia.
CEOMichael Kevin Handley, MBA
CEOMichael Kevin Handley, MBA
Employees—
Employees—
HeadquartersFort Collins, Colorado
HeadquartersFort Collins, Colorado
Founded2003
Founded2003
Employees—
Employees—
CBLI Key Statistics
Market cap7.10K
Market cap7.10K
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume307.90K
Average volume307.90K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$0.125
52 Week high$0.125
52 Week low—
52 Week low—
Stock Snapshot
Cleveland BioLabs(CBLI) stock is priced at $3.43, giving the company a market capitalization of 7.1K.
On 2026-03-30, Cleveland BioLabs(CBLI) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for Cleveland BioLabs(CBLI) stock has reached 0, versus its average volume of 307.9K.
People also own
Based on the portfolios of people who own CBLI. This list is generated using Robinhood data, and it’s not a recommendation.